Latest Roche News & Updates

See the latest news and media coverage for Roche. We track all announcements, press releases, and industry mentions in real time, all in one place.

Roche

Pharmaceuticals and diagnostics company

roche.com

Headquarters: Switzerland 🇨🇭 , Switzerland
Company type: Public company
Number of employees: 100,000+

Last updated Today

Latest news about Roche

In short: Roche achieved multiple FDA milestones for cancer therapies and advanced its obesity pipeline while warning of Swiss labor and price pressures.

Company announcements

June 12 Roche

Roche PTEN diagnostic gets FDA approval for prostate cancer

The Ventana PTEN assay helps identify patients with PTEN-deficient prostate cancer for targeted therapy with TRUQAP.

June 11 Roche

Roche's Tecentriq gets FDA Priority Review for colon cancer

The filing is supported by phase III ATOMIC data showing Tecentriq plus chemotherapy halves recurrence risk compared to chemotherapy alone.

June 8 Roche

Roche collaborates with Nurix to co-develop BTK degrader bexobrutideg

The deal covers oncology, immunology, and neurology. Roche pays $700M upfront, potential $2.3B total.

June 2 Roche

Roche announces FDA acceptance of giredestrant NDA

The NDA is for ER-positive early-stage breast cancer, based on phase III lidERA data showing 30% risk reduction in invasive disease recurrence or death.

Media coverage

Today wallstreet:online

New study data: Roche before breakthrough: Now a billion-dollar opportunity beckons | wallstreetONLINE - 18.06.2026

The US drug authority is reviewing a new Roche combination against aggressive lymphatic cancer. Study data show clear benefits for patients.

Today cash

Roche submits application for Lunsumio-Polivy combination

Roche has submitted a supplemental application to the US Food and Drug Administration (FDA) for the combination of Lunsumio Velo and Polivy for the treatment of adults with an aggressive form of...

Today Stock Titan

Roche’s outpatient-ready lymphoma combo clears FDA filing review

FDA review is now underway for Lunsumio VELO plus Polivy in relapsed or refractory LBCL. Decision due by Feb. 9, 2027, after SUNMO data.

Today Las Vegas Sun

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the...

Never miss news about Roche

Track Roche and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.